Skip to content
The Policy VaultThe Policy Vault

MycamineCareFirst (Caremark)

treatment of same infections without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months

Initial criteria

  • limitations: safety and effectiveness not established for treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months
  • not adequately studied in endocarditis, osteomyelitis, and meningoencephalitis due to Candida
  • efficacy not established against infections caused by fungi other than Candida